Effect of Hesperetin on Isoprenaline-induced Hypertrophy of H9C2 Cardiomyocytes

Area of Science:

• Cardiovascular Research
• Cell Biology
• Pharmacology

Background:

• Cardiac hypertrophy is a significant risk factor for heart failure.
• Isoproterenol is commonly used to induce experimental models of cardiac hypertrophy.
• Hesperetin, a flavonoid, has shown potential cardioprotective effects.

Purpose of the Study:

• To investigate the effect of hesperetin on isoproterenol-induced H9C2 cardiomyocyte hypertrophy.
• To elucidate the underlying mechanism involving autophagy.

Main Methods:

• H9C2 cardiomyocytes were treated with isoproterenol and varying concentrations of hesperetin.
• Cell area, beta-myosin heavy chain (β-MHC) mRNA expression, and microtubule-associated protein 1A/1B-light chain 3 II (LC3II) expression were measured.
• Time-course experiments were conducted to assess the effects of hesperetin over 6, 12, and 24 hours.

Main Results:

• Hesperetin significantly reduced the isoproterenol-induced increase in H9C2 cardiomyocyte area.
• Hesperetin decreased the expression of the cardiac hypertrophy marker β-MHC mRNA.
• Hesperetin treatment led to an increased expression level of the autophagy marker LC3II.

Conclusions:

• Hesperetin demonstrates a protective effect against isoproterenol-induced cardiac hypertrophy in H9C2 cells.
• The mechanism of hesperetin's action may involve the activation of autophagy.
• Hesperetin shows potential as a therapeutic agent for managing cardiac hypertrophy.